Shots: Results of P-III ODYSSEY OUTCOMES assessing PRALUENT(alirocumab) IV (N= 18,924), having an acute coronary syndrome (ACS), such as a heart attack, b/w 1-12 mos before being enrolled The US FDA has set a PDUFA date of 28 April, 2019. ODYSSEY OUTCOMES demonstrated a reduction in overall risk of MACE Additionally, FDA updated Praluent PI […]Read More
